Fierce Pharma June 24, 2024
Over the years, ANI Pharmaceuticals has grown itself in part through a series of strategic acquisitions. Now, the company has inked a sizable deal to get its hands on ophthalmology specialist Alimera Sciences and its two approved commercial drugs.
For $5.50 per share and a contingent value right (CVR) worth up to $0.50 per share, ANI has agreed to purchase Alimera and its ophthalmology offerings Iluvien and Yutiq. The CVR is payable to Alimera’s investors if the acquired company hits certain revenue targets in 2026 and 2027, ANI said in a Monday press release.
The deal values Alimera at about $381 million in up front cash, and the price represents a 75% premium to Alimera’s closing share price on Friday....
Today's Sponsors
Today's Sponsor